On July 11, 2025, MiNK Therapeutics announced positive results from a patient's case study published in Nature's Oncogene, where a single infusion of their iNKT cell therapy, agenT-797, led to a complete remission in a treatment-resistant testicular cancer case. Additionally, data presented at the AACR Immuno-Oncology meeting showed promising results for patients with gastric cancer in ongoing clinical trials.